Merck (MRK)'s CEO Has a "Better Hand," Says Jim Cramer
Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world.
Merck Sharp & Dohme Corp. (MRK)
This company is not actively trading or the ticker does belong to another company in our database now. The symbol (MRK) is currently associated with the following stock: Merck & Co. Inc. (MRK)
Sector: Pharmaceutical Preparations
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.22 | 550 | $18,268.75 | 750 | 2006-01-18 | Filing | |
| $45.65 | 200 | $9,130.56 | 200 | 2002-09-24 | Filing |
News See All
12 Stocks on Jim Cramer's Radar
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed comments by Treasury Secretary Scott Bessent, where he remarked that he saw inflation in the US dropping significantly in 2026...
Merck & Co., Inc. (MRK) Sees Mixed Analyst Views as Europe Advances WINREVAIR Review
On the same day, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an expanded indication for MRK’s WINREVAIR (sotatercept...
BofA Turns More Positive on Merck (MRK) Pipeline
On December 15, BofA raised its price target on Merck & Co., Inc. (NYSE:MRK) to $120 from $105 and kept a Buy rating.
12 Best Dogs of the Dow to Invest in
Research published in the International Journal of Trade, Economics and Finance points to the work of Michael O’Higgins and John Downes, authors of Beating the Dow, who laid out a simple but influential...
9 Most Undervalued Pharma Stocks to Buy Right Now
The U.S. pharmaceutical industry in 2025 remains one of the nation’s most dynamic and profitable economic sectors.
Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves
On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock.
15 Best Blue-Chip Stocks with Growing Dividends
Dividend stocks have fallen behind the broader market this year as investors have piled into tech and AI names. Still, that doesn’t take away from their long-term value.
Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104
Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co., Inc.
11 Cheap NYSE Stocks to Buy Now
On December 9, Kevin Mahn from Hennion & Walsh and Victoria Greene from G Squared Private Wealth appeared on CNBC television for an interview to discuss their 2026 market outlook.
Hedge Fund Resource Center Billionaire Hedge Funds
